Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574080 · ClinicalTrials.gov registry record · Phase 3
UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
A Phase 3 study, sponsored by University of Arkansas.
- Terminated
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT00574080 is a Phase 3 study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 20 participants.
The verdict
NCT00574080, a Phase 3 study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
Add three drugs, bortezomib, thalidomide, and dexamethasone (VTD) to the high dose chemotherapy regimen immediately before transplant (DPACE/Melphalan) to try to improve myeloma response and acquire longer survival for participants.
Interventions
- DRUG Interim/Maintenance Dexamethasone
- DRUG Induction/Consolidation Dexamethasone
- DRUG Induction/Consolidation Cisplatin
- DRUG Induction/Consolidation Adriamycin
- DRUG InductionConsolidation Cyclophosphamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-07 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00574080
The ClinicalTrials.gov registry entry for NCT00574080 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Interim/Maintenance Dexamethasone is the first listed.
NCT00574080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00574080 about?
NCT00574080 is a clinical study titled "UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide". Add three drugs, bortezomib, thalidomide, and dexamethasone (VTD) to the high dose chemotherapy regimen immediately before transplant (DPACE/Melphalan) to try to improve myeloma response and acquire longer survival for participants.
What is the current status of trial NCT00574080?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2006-07. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00574080?
The interventions under investigation include: Interim/Maintenance Dexamethasone (DRUG), Induction/Consolidation Dexamethasone (DRUG), Induction/Consolidation Cisplatin (DRUG), Induction/Consolidation Adriamycin (DRUG), InductionConsolidation Cyclophosphamide (DRUG).
Who is sponsoring clinical trial NCT00574080?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.